Business
Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development
(TheNewswire) Toronto, Ontario – TheNewswire – September 1, 2022 ...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development \n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Toronto, Ontario –\n \n \n TheNewswire – September 1,\n2022\n \n \n –\n \n \n Helix BioPharma Corp\n \n \n .\n \n \n (TSX:HBP) (“Helix” or the “Company”), a\nclinical-stage biopharmaceutical company that is developing unique\ntherapies in the field of immuno-oncology based on its proprietary\ntechnology platform DOS47, is pleased to announce the appointment of\nDr. Gabrielle M Siegers, MA, Ph.D., as the Head of R&D based out\nof the Company’s lab in Edmonton.\n \n \n \n \n Dr. Siegers comes to Helix from IN8bio, a US biotech\ncompany developing Gamma Delta T Cell immunotherapies for cancer,\nwhere she served as Senior Scientist/Gamma Delta T Cell Specialist.\nPrior to this, Dr. Siegers was a Research Associate with the\nDepartment of Experimental Oncology at the University of Alberta\nfollowing postdoctoral studies in Dr. Lynne-Marie Postovit’s\nlaboratory, where she studied how the tumour microenvironment impacts\nimmune cell function.  Prior to this, Dr. Siegers was a Postdoctoral\nFellow in the laboratory of Dr. Paula Foster, a world-renowned\ncellular MRI expert at Robarts Research Institute, where she continued\nresearch begun in the Translational Cell Therapy Program with Dr.\nArmand Keating at the Princess Margaret Hospital.\n \n \n \n \n “We are delighted to welcome Dr. Gabrielle Siegers as\na key addition to the team. We are confident that she will lead our\nR&D team toward success and help them to make significant\nbreakthroughs in the field of immune oncology”, said Artur Gabor,\nHelix’s Chief Executive Officer.\n \n \n \n \n \n \n Dr. Siegers stated,\n\"I am delighted to join Helix in this exciting capacity, to put\nmy knowledge and skills toward further development of Helix’s\npromising new cancer therapies for patients.\"\n \n \n \n \n Gabrielle Siegers Bio\n \n \n \n \n Gabrielle M. Siegers (HBSc Guelph, MA Queen’s)\nobtained her PhD in Molecular Immunology at the Max Planck Institute\nfor Immunobiology and the University of Freiburg, Germany. Ms. Siegers\nreturned to Canada to conduct postdoctoral research at the Princess\nMargaret Hospital, Rob...